Drugs and test tools that help drug companies and clinics improve and measure real muscle strength rather than just muscle size.
Therapeutics & Biomarkers for Functional Muscle Strength
Peter Attia’s recent piece highlights the paradox that myostatin inhibitors can make muscles bigger without improving strength, exposing a costly blind spot in drug development. That gap creates a practical chance for drugs, rehab protocols, and biomarkers — and for tests clinics and trials can use to measure real functional strength.
Projected Score
as a side gig ☆☆☆☆☆ (0/5)
no money or audience ☆☆☆☆☆ (0/5)
with both ★★☆☆☆ (2/5)
Want this one researched? Commission the full dossier for $15: we research and write it, and you read it first. Then you choose — pay more to keep it exclusive, or do nothing and it goes public on this site. The score above is our forecast for a dossier we haven’t written yet.
The news behind it
- Oct 4, 2026 Peter Attia: Myostatin inhibitors and the paradox of larger but weaker muscles
